GB1005364A
(en)
|
1963-09-12 |
1965-09-22 |
Du Pont |
Columbium-base alloys
|
US6566560B2
(en)
|
1999-03-22 |
2003-05-20 |
Immugen Pharmaceuticals, Inc. |
Resorcinolic compounds
|
US6403126B1
(en)
|
1999-05-26 |
2002-06-11 |
Websar Innovations Inc. |
Cannabinoid extraction method
|
US6949582B1
(en)
*
|
1999-05-27 |
2005-09-27 |
Wallace Walter H |
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
|
ES2164584A1
(es)
|
2000-02-11 |
2002-02-16 |
Univ Madrid Complutense |
Terapia con cannabinoides para el tratamiento de tumores cerebrales.
|
ES1045342Y
(es)
|
2000-02-11 |
2001-02-16 |
Alvarez Manuel Couto |
Expositor giratorio para postales, fotos y similares.
|
US20040039048A1
(en)
|
2000-02-11 |
2004-02-26 |
Manuel Guzman Pastor |
Therapy with cannabinoid compounds for the treatment of brain tumors
|
US6448288B1
(en)
|
2000-05-17 |
2002-09-10 |
University Of Massachusetts |
Cannabinoid drugs
|
IL136839A
(en)
|
2000-06-16 |
2006-12-10 |
Yissum Res Dev Co |
Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
|
EP1326996A4
(en)
|
2000-09-14 |
2005-08-24 |
Univ California |
ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA
|
DE10051427C1
(de)
|
2000-10-17 |
2002-06-13 |
Adam Mueller |
Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
|
US7025992B2
(en)
|
2001-02-14 |
2006-04-11 |
Gw Pharma Limited |
Pharmaceutical formulations
|
GB0103638D0
(en)
*
|
2001-02-14 |
2001-03-28 |
Gw Pharmaceuticals Ltd |
Pharmaceutical formulations
|
US6730330B2
(en)
|
2001-02-14 |
2004-05-04 |
Gw Pharma Limited |
Pharmaceutical formulations
|
GB2380129B
(en)
|
2001-02-14 |
2004-08-11 |
Gw Pharma Ltd |
Pharmaceutical formulations
|
IL157130A0
(en)
|
2001-02-14 |
2004-02-08 |
Gw Pharma Ltd |
A cannabis based pharmaceutical formulation
|
CH695661A5
(de)
|
2001-03-06 |
2006-07-31 |
Forsch Hiscia Ver Fuer Krebsfo |
Pharmazeutische Zusammensetzung.
|
GB2381450B
(en)
|
2001-10-31 |
2006-05-31 |
Gw Pharma Ltd |
Compositions for administration of natural or synthetic cannabinoids by vaporisation
|
GB0202385D0
(en)
*
|
2002-02-01 |
2002-03-20 |
Gw Pharma Ltd |
Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
|
US8034843B2
(en)
|
2002-02-01 |
2011-10-11 |
Gw Pharma Limited |
Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
|
US20080057117A1
(en)
|
2002-02-15 |
2008-03-06 |
Forschungs Institut Miscia Verenfur Krebsforschung |
Pharmaceutical composition made up of cannibus extracts
|
IL148244A0
(en)
|
2002-02-19 |
2002-09-12 |
Yissum Res Dev Co |
Anti-nausea and anti-vomiting activity of cannabidiol compounds
|
US7285687B2
(en)
|
2002-04-25 |
2007-10-23 |
Virginia Commonwealth University |
Cannabinoids
|
ITPD20020138A1
(it)
|
2002-05-24 |
2003-11-24 |
Matteo Bevilacqua |
Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
|
DE10226494A1
(de)
|
2002-06-14 |
2004-01-08 |
Lts Lohmann Therapie-Systeme Ag |
Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
|
GB2391865B
(en)
|
2002-08-14 |
2005-06-01 |
Gw Pharma Ltd |
Improvements in the extraction of pharmaceutically active components from plant materials
|
PL215220B1
(pl)
|
2002-08-14 |
2013-11-29 |
Gw Pharma Ltd |
Ciekly preparat farmaceutyczny
|
US10538373B2
(en)
|
2002-08-14 |
2020-01-21 |
Gw Pharma Limited |
Pharmaceutical formulation
|
US6946150B2
(en)
|
2002-08-14 |
2005-09-20 |
Gw Pharma Limited |
Pharmaceutical formulation
|
PT2311475T
(pt)
|
2002-08-14 |
2016-09-22 |
Gw Pharma Ltd |
Extração de canabinoides farmaceuticamente ativos a partir de material vegetal
|
GB0222077D0
(en)
|
2002-09-23 |
2002-10-30 |
Gw Pharma Ltd |
Methods of preparing cannabinoids from plant material
|
GB2394894B
(en)
|
2002-11-04 |
2005-08-31 |
G W Pharma Ltd |
New use for pharmaceutical composition
|
US20040110828A1
(en)
|
2002-11-27 |
2004-06-10 |
Chowdhury Dipak K. |
Tetrahydrocannabinol compositions and methods of manufacture and use thereof
|
GB2414933B
(en)
|
2004-06-08 |
2009-07-15 |
Gw Pharma Ltd |
Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
|
GB2418612A
(en)
|
2004-10-01 |
2006-04-05 |
Gw Pharma Ltd |
Inhibition of tumour cell migration with cannabinoids
|
CA2586358C
(en)
|
2004-11-16 |
2015-11-24 |
Gw Pharma Limited |
Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor
|
GB0425248D0
(en)
|
2004-11-16 |
2004-12-15 |
Gw Pharma Ltd |
New use for cannabinoid
|
AU2006231452B2
(en)
|
2005-04-01 |
2011-05-26 |
Intezyne Technologies, Inc. |
Polymeric micelles for drug delivery
|
US7968594B2
(en)
|
2005-04-27 |
2011-06-28 |
Gw Pharma Limited |
Pharmaceutical compositions for the treatment of pain
|
BRPI0610364A2
(pt)
|
2005-05-13 |
2010-06-15 |
Unimed Pharmaceuticals Inc |
tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
|
TWI366460B
(en)
|
2005-06-16 |
2012-06-21 |
Euro Celtique Sa |
Cannabinoid active pharmaceutical ingredient for improved dosage forms
|
US20070060638A1
(en)
|
2005-08-26 |
2007-03-15 |
Olmstead Mary C |
Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
|
GB2432312A
(en)
|
2005-11-01 |
2007-05-23 |
Gw Pharma Ltd |
Pharmaceutical compositions for the treatment of pain
|
GB2434312B
(en)
|
2006-01-18 |
2011-06-29 |
Gw Pharma Ltd |
Cannabinoid-containing plant extracts as neuroprotective agents
|
US8729133B2
(en)
|
2006-02-28 |
2014-05-20 |
Cornell University |
Method for treating cancer
|
US9877928B2
(en)
|
2006-05-30 |
2018-01-30 |
Air Systems, Inc. |
Gear drive damper
|
GB2438682A
(en)
*
|
2006-06-01 |
2007-12-05 |
Gw Pharma Ltd |
New use for cannabinoids
|
GB2439393B
(en)
|
2006-06-23 |
2011-05-11 |
Gw Pharma Ltd |
Cannabinoids for use in the treatment of neuropathic pain
|
CN101516333A
(zh)
|
2006-08-04 |
2009-08-26 |
英西斯治疗学股份有限公司 |
水性屈大麻酚制剂
|
WO2008021394A2
(en)
|
2006-08-15 |
2008-02-21 |
Theraquest Biosciences, Llc |
Pharmaceutical formulations of cannabinoids and method of use
|
US20080188461A1
(en)
|
2007-02-01 |
2008-08-07 |
Regents Of The University Of Michigan |
Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
|
CN101040855A
(zh)
|
2007-04-12 |
2007-09-26 |
杨喜鸿 |
含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
|
GB2448535A
(en)
|
2007-04-19 |
2008-10-22 |
Gw Pharma Ltd |
New use for cannabinoid-containing plant extracts
|
US9084771B2
(en)
|
2007-05-17 |
2015-07-21 |
Sutter West Bay Hospitals |
Methods and compositions for treating cancer
|
GB2449691A
(en)
|
2007-05-31 |
2008-12-03 |
Gw Pharma Ltd |
A reference plant lacking medicinal active compound expression
|
GB2450753B
(en)
|
2007-07-06 |
2012-07-18 |
Gw Pharma Ltd |
New Pharmaceutical formulation
|
EP2023121A1
(en)
|
2007-07-06 |
2009-02-11 |
Bp Oil International Limited |
Optical cell
|
MX2010001242A
(es)
|
2007-07-30 |
2010-07-02 |
Alltranz Inc |
Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
|
EP2184983A1
(en)
|
2007-08-06 |
2010-05-19 |
Insys Therapeutics Inc. |
Oral cannabinoid liquid formulations and methods of treatment
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
GB2459637B
(en)
|
2008-01-21 |
2012-06-06 |
Gw Pharma Ltd |
New use for cannabinoids
|
LT2280687T
(lt)
|
2008-03-26 |
2019-08-26 |
Stichting Sanammad |
Kramtomosios gumos kompozicijos, apimančios kanabinoidus
|
GB2478074B
(en)
|
2008-06-04 |
2012-12-26 |
Gw Pharma Ltd |
Anti-tumoural effects of cannabinoid combinations
|
GB2478072B
(en)
|
2008-06-04 |
2012-12-26 |
Gw Pharma Ltd |
Anti-tumoural effects of cannabinoid combinations
|
GB2475183B
(en)
|
2008-06-04 |
2011-11-23 |
Gw Pharma Ltd |
Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
|
GB2471987B
(en)
|
2008-06-04 |
2012-02-22 |
Gw Pharma Ltd |
Anti-tumoural effects of cannabinoid combinations
|
WO2010012506A1
(en)
|
2008-07-31 |
2010-02-04 |
Bionorica Research Gmbh |
Cannabinoids for use in treating or preventing cognitive impairment and dementia
|
US20120202891A1
(en)
|
2009-04-29 |
2012-08-09 |
University Of Kentucky Research Foundation |
Cannabinoid-Containing Compositions and Methods for Their Use
|
KR101701544B1
(ko)
|
2009-06-29 |
2017-02-01 |
벤더 아날리티컬 홀딩 비.브이. |
폴리옥사졸린 및 생리활성제를 포함하는 약물 전달 시스템
|
GB2471523A
(en)
|
2009-07-03 |
2011-01-05 |
Gw Pharma Ltd |
Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
|
US8735374B2
(en)
|
2009-07-31 |
2014-05-27 |
Intelgenx Corp. |
Oral mucoadhesive dosage form
|
GB2478595B
(en)
|
2010-03-12 |
2018-04-04 |
Gw Pharma Ltd |
Phytocannabinoids in the treatment of glioma
|
GB2479153B
(en)
*
|
2010-03-30 |
2014-03-19 |
Gw Pharma Ltd |
The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
|
GB2487183B
(en)
|
2011-01-04 |
2018-10-03 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
|
TWI583374B
(zh)
*
|
2010-03-30 |
2017-05-21 |
Gw伐瑪有限公司 |
使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
|
NZ605887A
(en)
|
2010-08-04 |
2014-08-29 |
Gruenenthal Gmbh |
Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
|
WO2012033478A1
(en)
|
2010-09-07 |
2012-03-15 |
Murty Pharmaceuticals, Inc. |
An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
|
US8895536B2
(en)
|
2010-10-29 |
2014-11-25 |
Infirst Healthcare Ltd. |
Compositions and methods for treating chronic inflammation and inflammatory diseases
|
GB2487712B
(en)
|
2011-01-04 |
2015-10-28 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
|
KR20120080675A
(ko)
|
2011-01-08 |
2012-07-18 |
주식회사한국전통의학연구소 |
마자인 추출물을 포함하는 백혈병 치료용 조성물 및 건강 기능성 식품
|
CA2737447A1
(en)
|
2011-04-27 |
2012-10-27 |
Antony Paul Hornby |
Hayley's comet
|
GB201111261D0
(en)
*
|
2011-07-01 |
2011-08-17 |
Gw Pharma Ltd |
Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
|
EP2747770A1
(en)
|
2011-08-26 |
2014-07-02 |
BIAL - Portela & Cª S.A. |
Treatments involving eslicarbazepine acetate or eslicarbazepine
|
GB2495118B
(en)
|
2011-09-29 |
2016-05-18 |
Otsuka Pharma Co Ltd |
A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
|
GB2496687A
(en)
|
2011-11-21 |
2013-05-22 |
Gw Pharma Ltd |
Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
|
US9254272B2
(en)
|
2011-11-30 |
2016-02-09 |
Sutter West Bay Hospitals |
Resorcinol derivatives
|
GB2504263B
(en)
|
2012-06-08 |
2015-09-16 |
Gw Pharma Ltd |
Synergistic therapies for neuroprotection
|
DE102012105063C5
(de)
|
2012-06-12 |
2023-09-14 |
Thc Pharm Gmbh The Health Concept |
Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
|
US9345771B2
(en)
|
2012-10-04 |
2016-05-24 |
Insys Development Company, Inc. |
Oral cannabinoid formulations
|
CN103110582A
(zh)
|
2013-03-04 |
2013-05-22 |
上海医药工业研究院 |
大麻酚类化合物微乳剂及其制备方法
|
MX2015013202A
(es)
|
2013-03-15 |
2016-04-07 |
Biotech Inst Llc |
Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
|
EP2976074B1
(en)
|
2013-03-19 |
2020-01-01 |
Universitat Pompeu-Fabra |
Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
GB2516814B
(en)
|
2013-06-19 |
2016-08-31 |
Otsuka Pharma Co Ltd |
Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
|
GB2515312A
(en)
|
2013-06-19 |
2014-12-24 |
Gw Pharma Ltd |
The use of phytocannabinoids in the treatment of ovarian carcinoma
|
US20150181924A1
(en)
|
2013-10-31 |
2015-07-02 |
Michael R. Llamas |
Cannabidiol liquid composition for smoking
|
US9259449B2
(en)
|
2014-01-07 |
2016-02-16 |
Joshua Michael Raderman |
Method for modifying THC content in a lipid-based extract of cannabis
|
US10052339B2
(en)
|
2014-03-21 |
2018-08-21 |
Bodybio Inc. |
Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
|
CN106999598B
(zh)
|
2014-05-29 |
2022-02-08 |
鲜切发展有限责任公司 |
稳定的大麻素类化合物制剂
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
GB2527599A
(en)
|
2014-06-27 |
2015-12-30 |
Gw Pharma Ltd |
Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
|
GB2527590A
(en)
|
2014-06-27 |
2015-12-30 |
Otsuka Pharma Co Ltd |
Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
|
GB2527591A
(en)
|
2014-06-27 |
2015-12-30 |
Gw Pharma Ltd |
7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
|
WO2016022936A1
(en)
|
2014-08-07 |
2016-02-11 |
Murty Pharmaceuticals, Inc. |
An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
|
CA2859934A1
(en)
|
2014-09-22 |
2016-03-22 |
A. Paul Hornby |
Hayley's comet ii
|
GB2531283A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
|
GB2531278A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
GB2531281A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
GB2531280A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
CA3135893C
(en)
|
2014-10-21 |
2023-11-14 |
United Cannabis Corp. |
Cannabis extracts and methods of preparing and using same
|
US20180303791A1
(en)
|
2014-11-26 |
2018-10-25 |
One World Cannabis Ltd |
Synergistic use of cannabis for treating multiple myeloma
|
US20180353461A1
(en)
|
2014-12-04 |
2018-12-13 |
Servicio Andaluz De Salud |
Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues
|
US10172786B2
(en)
|
2014-12-16 |
2019-01-08 |
Axim Biotechnologies, Inc. |
Oral care composition comprising cannabinoids
|
WO2016118391A1
(en)
|
2015-01-25 |
2016-07-28 |
India Globalization Capital, Inc. |
Composition and method for treating seizure disorders
|
EP3265081A4
(en)
|
2015-03-02 |
2018-11-21 |
Afgin Pharma, Llc |
Topical regional neuro-affective therapy with cannabinoids
|
AU2016231788A1
(en)
|
2015-03-19 |
2017-10-12 |
One World Cannabis Ltd |
Preparations of cannabis emulsions and methods thereof
|
WO2016199148A1
(en)
|
2015-06-11 |
2016-12-15 |
One World Cannabis Ltd |
Novel cannabinoid combination therapies for multiple myeloma (mm)
|
GB2539472A
(en)
|
2015-06-17 |
2016-12-21 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2541191A
(en)
|
2015-08-10 |
2017-02-15 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2542155B
(en)
|
2015-09-09 |
2018-08-01 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of mental disorders
|
GB2542797A
(en)
|
2015-09-29 |
2017-04-05 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of inflammatory skin diseases
|
GB2548873B
(en)
|
2016-03-31 |
2020-12-02 |
Gw Res Ltd |
Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
|
GB2551987A
(en)
|
2016-07-01 |
2018-01-10 |
Gw Res Ltd |
Oral cannabinoid formulations
|
GB2551986A
(en)
|
2016-07-01 |
2018-01-10 |
Gw Res Ltd |
Parenteral formulations
|
GB2551985B
(en)
|
2016-07-01 |
2019-01-30 |
Gw Res Ltd |
Novel formulation
|
GB2553139A
(en)
|
2016-08-25 |
2018-02-28 |
Gw Res Ltd |
Use of cannabinoids in the treatment of multiple myeloma
|
GB2557921A
(en)
|
2016-12-16 |
2018-07-04 |
Gw Res Ltd |
Use of cannabinoids in the treatment of angelman syndrome
|
GB2559774B
(en)
|
2017-02-17 |
2021-09-29 |
Gw Res Ltd |
Oral cannabinoid formulations
|
GB2560019A
(en)
|
2017-02-27 |
2018-08-29 |
Gw Res Ltd |
Use of cannabinoids in the treatment of leukaemia
|
GB2564383B
(en)
|
2017-06-23 |
2021-04-21 |
Gw Res Ltd |
Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
|
GB201715919D0
(en)
|
2017-09-29 |
2017-11-15 |
Gw Res Ltd |
use of cannabinoids in the treatment of epilepsy
|
GB2568471B
(en)
|
2017-11-15 |
2022-04-13 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2568929A
(en)
|
2017-12-01 |
2019-06-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2569961B
(en)
|
2018-01-03 |
2021-12-22 |
Gw Res Ltd |
Pharmaceutical
|
GB2572126B
(en)
|
2018-01-03 |
2021-01-13 |
Gw Res Ltd |
Pharmaceutical
|
GB2572125B
(en)
|
2018-01-03 |
2021-01-13 |
Gw Res Ltd |
Pharmaceutical
|
GB2572737A
(en)
|
2018-01-24 |
2019-10-16 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB201806953D0
(en)
|
2018-04-27 |
2018-06-13 |
Gw Res Ltd |
Cannabidiol Preparations
|
GB2579179A
(en)
|
2018-11-21 |
2020-06-17 |
Gw Res Ltd |
Cannabidiol-type cannabinoid compound
|
GB2580881A
(en)
|
2018-11-30 |
2020-08-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2580653A
(en)
|
2019-01-21 |
2020-07-29 |
Gw Res Ltd |
Use of cannabinoids in the treatment of comorbidities associated with epilepsy
|
GB2581517A
(en)
|
2019-02-22 |
2020-08-26 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
GB2581987B
(en)
|
2019-03-06 |
2021-11-17 |
Gw Res Ltd |
Use of cannabidiol in combination with antibiotics
|
GB2584140A
(en)
|
2019-05-23 |
2020-11-25 |
Gw Res Ltd |
Use of cannabidiol in the treatment of epileptic spasms
|
GB2584341B
(en)
|
2019-05-31 |
2023-03-01 |
Gw Res Ltd |
Cannabinoid formulations
|
GB201910389D0
(en)
|
2019-07-19 |
2019-09-04 |
Gw Pharma Ltd |
Novel compounds, methods for their manufacture, and uses thereof
|
GB2586026A
(en)
|
2019-07-29 |
2021-02-03 |
Gw Res Ltd |
Use of cannabidol in the treatment of Dravet syndrome
|
GB2588576A
(en)
|
2019-08-27 |
2021-05-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
|
GB2588460A
(en)
|
2019-10-25 |
2021-04-28 |
Gw Res Ltd |
Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
|
GB2588457B
(en)
|
2019-10-25 |
2022-12-21 |
Gw Res Ltd |
Cannabinoid compound
|
GB2588461A
(en)
|
2019-10-25 |
2021-04-28 |
Gw Res Ltd |
Use of cannabidiol preparations in the treatment of absence epilepsy
|
GB201916849D0
(en)
|
2019-11-19 |
2020-01-01 |
Gw Res Ltd |
Cannabidiol-type cannabinoid compound
|
GB201916846D0
(en)
|
2019-11-19 |
2020-01-01 |
Gw Res Ltd |
Cannabidiol-type cannabinoid compound
|
GB201916974D0
(en)
|
2019-11-21 |
2020-01-08 |
Gw Res Ltd |
Cannabidol-type cannabinoid compound
|
GB201916977D0
(en)
|
2019-11-21 |
2020-01-08 |
Gw Res Ltd |
Cannibidol-type cannabinoid compound
|
GB201918846D0
(en)
|
2019-12-19 |
2020-02-05 |
Gw Res Ltd |
Oral cannabinoid formulations
|
GB202002754D0
(en)
|
2020-02-27 |
2020-04-15 |
Gw Res Ltd |
Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
|
GB2597281A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
|
GB2597318A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597315A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597312A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597313A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597323A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597321A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597301A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
|
GB2597316A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597309A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597322A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2600077A
(en)
|
2020-07-20 |
2022-04-27 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597311A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597317A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597308A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
|
GB2597279A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
|
GB2597306A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB2597285A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
GB202014250D0
(en)
|
2020-09-10 |
2020-10-28 |
Gw Res Ltd |
Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
US20220087951A1
(en)
|
2020-09-18 |
2022-03-24 |
GW Research Limited |
Use of cannabinoids in the treatment of epilepsy
|
GB2598922A
(en)
|
2020-09-18 |
2022-03-23 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
US11160757B1
(en)
|
2020-10-12 |
2021-11-02 |
GW Research Limited |
pH dependent release coated microparticle cannabinoid formulations
|
GB2601755A
(en)
|
2020-12-08 |
2022-06-15 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
|
TW202237554A
(zh)
|
2020-12-15 |
2022-10-01 |
英商吉偉研究有限公司 |
新穎化合物、其製備方法及其用途
|
GB2602019A
(en)
|
2020-12-15 |
2022-06-22 |
Gw Res Ltd |
Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
|
GB2606334A
(en)
|
2021-02-12 |
2022-11-09 |
Gw Res Ltd |
Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
|
US11815187B2
(en)
|
2022-01-26 |
2023-11-14 |
Maag Germany Gmbh |
3-port valve
|